Sepsis Guidelines Presentation symptoms labs antibiotic coverage , tell me all about sepsis with different types like abcess n treatment right through
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive data from Harrison's, Rosen's Emergency Medicine, and Sabiston Surgery. Let me compile the full presentation.
Sepsis: Complete Clinical Guide
1. Definition (Sepsis-3, 2016)
| Term | Definition |
|---|---|
| Sepsis | Life-threatening organ dysfunction caused by a dysregulated host response to infection. Operationalized as SOFA score increase ≥2 from baseline in a patient with suspected/confirmed infection |
| Septic Shock | Sepsis + persistent hypotension requiring vasopressors to maintain MAP >65 mmHg + lactate >2 mmol/L despite adequate fluid resuscitation |
Mortality in septic shock ranges from 35–54%.
— Harrison's Principles of Internal Medicine 22E, p. 2363
— Sabiston Textbook of Surgery, p. 948
— Sabiston Textbook of Surgery, p. 948
2. Pathophysiology (How Sepsis Kills)
Trigger: PAMPs (pathogen-associated molecular patterns from bacteria/fungi/viruses) + DAMPs (damage-associated molecular patterns from injured host cells) activate immune cells → massive cytokine release (IL-1β, IL-6, TNF-α).
Four key cascades:
- Inflammatory cascade — Proinflammatory cytokines cause systemic vasodilation, fever, capillary leak
- Endothelial dysfunction — Glycocalyx breakdown → proadhesive, procoagulant endothelium → increased permeability → interstitial edema → impaired oxygen delivery
- Coagulopathy / DIC — Tissue factor expression ↑ → thrombin generation → microthrombi → consumes clotting factors/platelets → hemorrhage risk
- Organ dysfunction — Tissue hypoperfusion + direct PAMP/DAMP cellular injury → multiorgan failure (kidneys, liver, lungs/ARDS, brain, heart)
The hemodynamic pattern is distributive shock: ↓SVR, ↑CO (compensatory), ↓CVP, ↓PCWP.
— Harrison's, p. 2363; Sabiston, p. 948
3. Presentation Symptoms
General (early):
- Fever (>38°C) or hypothermia (<35°C)
- Tachycardia (>90 bpm)
- Tachypnea (>22 breaths/min)
- Altered mental status / confusion / lethargy
- Myalgias, malaise, weakness
Localizing by source:
| Source | Presenting Symptoms |
|---|---|
| Pneumonia | Cough, sputum, pleuritis, hypoxia |
| Urosepsis (UTI/pyelonephritis) | Dysuria, flank pain, pyuria |
| Abdominal/Abscess | Abdominal pain, tenderness, nausea, vomiting |
| Skin/Soft tissue | Erythema, warmth, fluctuance (abscess), wound pain |
| Meningitis | Headache, neck stiffness, photophobia |
| Endocarditis | New murmur, embolic phenomena |
Late / Decompensated:
- Hypotension (SBP <90 mmHg)
- Oliguria / anuria
- Cool, mottled extremities (despite initial warm/flushed skin)
- Cyanosis
- Obtundation / coma
— Rosen's Emergency Medicine, p. 2757; Harrison's, p. 2363
4. Screening Tools
qSOFA (quick SOFA — bedside screening, no labs needed)
Score 1 point each:
- Respiratory rate ≥22 breaths/min
- GCS score <15 (altered mentation)
- Systolic BP ≤100 mmHg
≥2 points = high risk for poor outcome; warrants urgent workup for sepsis.
SOFA Score (full — requires labs)
Assesses 6 organ systems: PaO₂/FiO₂, platelets, bilirubin, MAP/vasopressors, GCS, creatinine. Increase ≥2 = sepsis.
SIRS Criteria (older, less specific — still clinically useful)
≥2 of:
- Temperature >38°C or <36°C
- HR >90 bpm
- RR >20 or PaCO₂ <32 mmHg
- WBC >12,000 or <4,000 or >10% bands
— Harrison's, p. 2363; Rosen's, p. 2756
5. Laboratory Investigations
Mandatory Initial Labs
| Test | What You're Looking For |
|---|---|
| CBC with differential | Leukocytosis (>12,000) or leukopenia (<4,000); bandemia ≥5–10% (immature neutrophils = bone marrow stress); thrombocytopenia (DIC) |
| Lactate (serum) | Lactate <2 mmol/L = low risk; 2–4 = concern; >4 mmol/L = 28% mortality — tissue hypoperfusion |
| BMP/CMP | Elevated creatinine (AKI); low bicarbonate/elevated anion gap (lactic acidosis); electrolyte disturbances; elevated bilirubin (biliary source or liver failure) |
| Coagulation panel (PT/PTT/INR, fibrinogen, D-dimer) | Elevated PT/PTT, ↓fibrinogen, ↑fibrin split products → DIC |
| Blood cultures × 2 | Ideally before antibiotics; positive in only 30–40% of clinical sepsis |
| Urinalysis + urine culture | Rule in/out urosepsis |
| LFTs | Elevated bilirubin → biliary sepsis; elevated transaminases → hepatic dysfunction |
| Lipase | If pancreatitis is a cause of SIRS |
| Procalcitonin (PCT) | Elevated in bacterial sepsis; used to guide antibiotic duration (Cochrane-endorsed for stewardship) |
| CRP | Non-specific marker of inflammation |
| ABG / VBG | Metabolic acidosis; PaO₂/FiO₂ ratio (ARDS) |
Microbiology
- Blood cultures × 2 (before antibiotics if possible — do not delay antibiotics for cultures)
- Urine, sputum, wound cultures as indicated
- CSF if meningitis suspected (after CT head)
- Gram stain all specimens
Imaging
- CXR: Pneumonia (focal infiltrate), ARDS (bilateral infiltrates), free air under diaphragm (bowel perforation)
- CT abdomen/pelvis: Intra-abdominal abscess, appendicitis, diverticulitis, bowel perforation, pelvic abscess
- CT head: Before LP; identify septic emboli from endocarditis
- Ultrasound abdomen: Cholecystitis, pelvic abscess, tubo-ovarian abscess
- MRI: Necrotizing fasciitis, epidural abscess
— Rosen's Emergency Medicine, p. 2757; Harrison's, p. 2363
6. Types of Sepsis by Source + Specific Treatment
6a. Abdominal/Intra-Abdominal Sepsis & Abscess
The gut is the most common source in surgical patients. Sources include appendicitis, diverticulitis, bowel perforation, cholangitis, cholecystitis, hepatic abscess, peritonitis, anorectal sepsis.
Key principle: Antibiotics + SOURCE CONTROL (drainage/surgery). Antibiotics alone are insufficient for abscess.
| Source | Likely Organisms | Antibiotic Coverage |
|---|---|---|
| Intra-abdominal (community) | Gram-negatives (E. coli, Klebsiella), anaerobes (Bacteroides fragilis) | Pip-tazo (piperacillin-tazobactam) OR ceftriaxone + metronidazole |
| Healthcare/post-op | As above + Pseudomonas, Enterococcus | Carbapenem (meropenem/imipenem) ± vancomycin |
| Biliary (cholangitis) | E. coli, Klebsiella, Enterococcus | Pip-tazo or carbapenem; add vancomycin if Enterococcus suspected |
| Hepatic abscess | Gram-negatives, anaerobes | Broad-spectrum + percutaneous CT-guided drainage for large abscesses |
| Anorectal abscess | Mixed fecal flora | Pip-tazo; surgical I&D is the definitive treatment (not antibiotics alone) |
Source Control Options:
- CT-guided percutaneous drainage (abscesses ≥3–4 cm)
- Surgical drainage / bowel resection
- ERCP + stenting for biliary obstruction (cholangitis)
"Large abscess cavities may require image-guided percutaneous drainage to expedite resolution of sepsis." — Mulholland & Greenfield's Surgery 7e
6b. Pulmonary Sepsis (Community-Acquired Pneumonia → Sepsis)
| Severity | Organisms | Empiric Therapy |
|---|---|---|
| CAP (non-ICU) | Streptococcus pneumoniae, atypicals (Legionella, Mycoplasma) | β-lactam (amoxicillin or ceftriaxone) + macrolide (azithromycin) |
| CAP (ICU/septic shock) | As above + gram-negatives | β-lactam + macrolide OR fluoroquinolone (levofloxacin) |
| HAP/VAP | Pseudomonas, MRSA, gram-negatives | Pip-tazo or cefepime + vancomycin or linezolid |
6c. Urological Sepsis (Urosepsis)
Most common source in community-acquired sepsis, especially elderly women.
| Source | Organisms | Empiric Therapy |
|---|---|---|
| Simple pyelonephritis with sepsis | E. coli, Klebsiella, Proteus | Ceftriaxone 2g IV q24h or ciprofloxacin |
| Complicated (obstruction, stones, healthcare-acquired) | As above + Pseudomonas, Enterococcus | Pip-tazo or meropenem ± vancomycin |
| Urosepsis with obstructed kidney | Any of above | Urgent urologic drainage (nephrostomy/stent) = source control |
6d. Skin & Soft Tissue Sepsis
| Condition | Organisms | Treatment |
|---|---|---|
| Cellulitis → bacteremia | Streptococcus, MSSA | Cefazolin IV; add vancomycin if MRSA risk |
| Abscess (skin/soft tissue) | S. aureus (MRSA common) | I&D first + TMP-SMX or doxycycline (MRSA); IV vancomycin if systemic sepsis |
| Necrotizing fasciitis | Polymicrobial or Group A Strep | Emergency surgical debridement + broad-spectrum (pip-tazo or carbapenem) + clindamycin (anti-toxin) |
"For otherwise healthy children with community-acquired sepsis, a third-generation cephalosporin…" — Rosen's Emergency Medicine
6e. CNS Sepsis (Meningitis/Encephalitis → Sepsis)
| Organism | Empiric Therapy |
|---|---|
| Bacterial meningitis (adult) | Ceftriaxone 2g IV q12h + vancomycin 15–20 mg/kg q8-12h + dexamethasone 0.15 mg/kg q6h × 4 days |
| Add ampicillin if: age >50, immunocompromised (Listeria coverage) | Ceftriaxone + vancomycin + ampicillin |
6f. Undifferentiated Sepsis (Unknown Source)
Per 2021 Surviving Sepsis Campaign Guidelines (Harrison's, p. 2364):
| If Pseudomonas NOT likely | Ceftriaxone or cefotaxime (3rd-gen cephalosporin) |
|---|---|
| If Pseudomonas likely (ICU, recent abx, bronchiectasis) | Cefepime OR pip-tazo OR meropenem |
| If MRSA risk (healthcare exposure, hospital-onset) | Add vancomycin or linezolid |
| If highly resistant gram-negatives (ESBL, KPC) | Two gram-negative agents + carbapenem |
| Antifungal (candida risk: abdominal surgery, TPN, liver failure, multi-site colonization) | Add echinocandin (micafungin/caspofungin) |
| COVID-19 sepsis | + Remdesivir |
| Influenza sepsis | + Oseltamivir |
7. Sepsis Management Bundle (Surviving Sepsis Campaign 2021)
Hour-1 Bundle
| Intervention | Target |
|---|---|
| Draw blood cultures | Before antibiotics (but do NOT delay abx) |
| Serum lactate | If >2 mmol/L → sepsis; if >4 → septic shock; remeasure if initial >2 |
| IV access | Peripheral or central |
| Broad-spectrum IV antibiotics | Within 1 hour of septic shock recognition. Every 1-hour delay = ~7–8% increase in mortality |
| IV crystalloid bolus | 30 mL/kg balanced crystalloid (Ringer's lactate preferred over NS) for hypotension or lactate ≥4 |
| Vasopressors | If MAP <65 mmHg after fluids → norepinephrine first-line |
Vasopressor Protocol
- Norepinephrine — 1st line (decreased mortality vs dopamine, less volume needed)
- Vasopressin — Add as 2nd agent (0.03–0.04 units/min)
- Epinephrine — Add if norepinephrine + vasopressin insufficient
- Dopamine — Reserve for select patients (e.g., bradycardia); higher arrhythmia risk
Fluid Management
- Initial resuscitation: 30 mL/kg crystalloid
- Reassess with dynamic measures (pulse pressure variation, stroke volume variation) after initial bolus
- Avoid excessive fluids (↑ ARDS, abdominal compartment syndrome risk)
Steroids
- Hydrocortisone 200 mg/day IV for vasopressor-dependent septic shock refractory to volume resuscitation
- Controversial for >3 decades; current recommendation is for low-dose only in vasopressor-dependent, volume-replete patients
Source Control
- Identify and remove all removable sources as rapidly as possible
- Remove infected IV catheters, chest tubes, urinary catheters
- Drain abscesses (percutaneous or surgical)
- Surgical debridement of necrotizing infections
Respiratory
- Target SpO₂ 92–96%
- Lung-protective ventilation if ARDS (tidal volume 6 mL/kg IBW, plateau pressure <30 cmH₂O)
Antibiotic Stewardship
- Daily reassessment for de-escalation once cultures result
- Procalcitonin-guided duration (shorter courses when PCT normalizes)
- Narrow spectrum once organism identified
— Harrison's, pp. 2363–2365; Sabiston Surgery, p. 948; Rosen's Emergency Medicine, pp. 2757–2759
8. Differential Diagnosis of Sepsis
Must always consider these mimics (especially in ICU):
- Cardiogenic shock (heart failure, MI)
- Pulmonary embolism
- Anaphylaxis
- DKA / HHS
- Adrenal crisis
- Pancreatitis
- Neuroleptic malignant syndrome
- Heat stroke
- Thyroid storm
- Drug-induced fever / overdose
"In a recent study of septic patients admitted to the ICU, 25% were retrospectively deemed to have sepsis mimics." — Harrison's, p. 2363
9. Prognosis & Monitoring
| Marker | Significance |
|---|---|
| Lactate 0–2 mmol/L | ~5% mortality |
| Lactate 2–4 mmol/L | ~9% mortality |
| Lactate >4 mmol/L | ~28% mortality |
| Rising lactate despite treatment | Persistent tissue hypoperfusion — escalate |
| Persistent vasopressor requirement | Increased mortality |
| New organ dysfunction (AKI, ARDS, DIC) | Each new organ failure worsens prognosis |
Goals of resuscitation: MAP ≥65 mmHg, UO ≥0.5 mL/kg/hr, lactate clearance ≥10%/2h, improved mentation.
Quick Reference Summary Table
| Category | Key Points |
|---|---|
| Sepsis-3 definition | Infection + SOFA ≥2 |
| Septic shock | Sepsis + vasopressors needed + lactate >2 |
| qSOFA | RR ≥22, GCS <15, SBP ≤100 (≥2 = high risk) |
| Labs | Lactate, CBC, BMP, LFTs, coags, cultures × 2, PCT |
| Antibiotics | Within 1 hour (shock); within 3 hours (no shock) |
| Undifferentiated sepsis | Ceftriaxone ± pip-tazo; add vancomycin if MRSA risk |
| Abdominal/abscess | Pip-tazo or carbapenem + surgical/percutaneous drainage |
| Urosepsis | Ceftriaxone; pip-tazo if complicated; drain obstruction |
| Skin/soft tissue | Vancomycin (MRSA) + I&D; surgery for necrotizing fasciitis |
| Fluids | 30 mL/kg balanced crystalloid |
| Vasopressors | Norepinephrine 1st; vasopressin 2nd |
| Steroids | Hydrocortisone 200 mg/day — only if vasopressor-dependent |
| Source control | As rapid as possible — always |
This is a shared conversation. Sign in to Orris to start your own chat.